Expansion of the homeostasis model assessment of β-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: IHOMA2

Diabetes Care

Volumn 36, Issue 8, 2013, Pages 2324-2330

  Hill, Nathan R ^a,b   Levy, Jonathan C ^a,b   Matthews, David R ^a,b,c  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b Oxford Biomedical Research Centre ^*  (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2; INSULIN; SLC5A2 PROTEIN, HUMAN;

24 VARIABLE HOMEOSTASIS MODEL ASSESSMENT; ANALYTICAL PARAMETERS; ARTICLE; CELL FUNCTION; COMPUTER PROGRAM; COMPUTER SIMULATION; GLUCOSE TRANSPORT; HUMAN; INSULIN RESISTANCE; MATHEMATICAL MODEL; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHYSIOLOGICAL PROCESS; PREDICTIVE VALUE; PROTEIN SYNTHESIS INHIBITION; URINARY EXCRETION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MODELS, BIOLOGICAL; SODIUM-GLUCOSE TRANSPORTER 2; THIAZOLIDINEDIONES;

EID: 84886032708     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-0607     Document Type: Article

References (27)

1. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223
2. Harano Y, Ohgaku S, Hidaka H, et al. Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity. J Clin Endocrinol Metab 1977;45:1124-1127
3. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236: E667-E677
4. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001; 24:539-548
5. Mari A. Mathematical modeling in glucose metabolism and insulin secretion. Curr Opin Clin Nutr Metab Care 2002;5:495-501
6. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
7. Turner RC, Rudenski AS, Matthews DR, Levy JC, O'Rahilly SP, Hosker JP. Application of structural model of glucoseinsulin relations to assess beta-cell function and insulin sensitivity. Horm Metab Res Suppl 1990;24:66-71
8. Levy JC, Matthews DR, Hermans MP. Correct homeostasismodel assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998;21:2191-2192
9. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495
10. McAuley KA, Mann JI, Chase JG, Lotz TF, Shaw GM. Point: HOMA-satisfactory for the time being: HOMA: the best bet for the simple determination of insulin sensitivity, until something better comes along. Diabetes Care 2007;30:2411-2413
11. Hockaday D, Sayyad M, Yajnik C. Counterpoint: appreciating homeostasis model assessment: more useful earlier rather than later. Diabetes Care 2007;30:2414-2418
12. Hosker JP, Burnett MA, Davies EG, Harris EA, Turner RC. Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients. Diabetologia 1985;28: 809-814
13. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53:1187-1194
14. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-38
15. Altman DG. Pratical Statistics for Medical Research. London, Chapman&Hall, 1991
16. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P; QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005;22:399-405
17. SchernthanerG,MatthewsDR,Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a doubleblind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-6076
18. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, PfisterM. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85:513-519
19. Cook JT, Page RC, O'Rahilly S, et al. Availability of type II diabetic families for detection of diabetes susceptibility genes. Diabetes 1993;42:1536-1543
20. Ferrannini E, Ramos SJ, Salsali A, TangW, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217-2224
21. Sugiyama Y, Shimura Y, Ikeda H. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneimittelforschung 1990;40:436-440
22. Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl 2001:13-18
23. Gastaldelli A, Miyazaki Y, Mahankali A, et al. The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 2006;29:2275-2281
24. Cobelli C, Pacini G, Toffolo G, et al. Estimation of insulin sensitivity and glucose clearance from minimal model: new insights from labeled IVGTT. Am J Physiol 1986;250:E591-E598
25. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993; 42:1663-1672
26. Jaqaman K, Danuser G. Linking data to models: data regression. Nat Rev Mol Cell Biol 2006;7:813-819
27. Hosker JP, Matthews DR, Rudenski AS, et al. Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man. Diabetologia 1985;28:401-411